What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Unizony et al. Case series of tocilizumab + 8 weeks steroid in GCA. 30 patients, 50% new 50% relapsing. 77% in sustained remission at week 52! No vision loss. Exciting, needs an RCT @RheumNow #EULAR2022 OP0185 https://t.co/ohBYIWYxBC https://t.co/fsn4x17Hwv
Janet Pope Janetbirdope
3 years 6 months ago
#Behcets. If topical oracort / steroids don’t work for Mucosal ulcers consider topical #tacrolimus https://t.co/7ZiLfdwZoP
TheDaoIndex KDAO2011
3 years 6 months ago
New #SLE drug to pay attention to!
iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and reduce IFN sig while enhancing regulatory T cells- Prof T Dorner #EULAR2022 @rheumnow https://t.co/q39pxK3gFJ
Aurelie Najm AurelieRheumo
3 years 6 months ago
Spanish safety registry BIOBADASER 3.0:
*9000+ pts with IMID treated w/ bio or tsDMARDS
*352 pts w/ prior malignancy
*32 incident malignancies
-> 27 events/1000PY
NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups
@RheumNow #EULAR2022
OP0138 https://t.co/8IyC6NdGCF
Dr. Antoni Chan synovialjoints
3 years 6 months ago
The PROOF study showed the predictors of radiographic progression included male gender HR 3.16, good response to NSAIDs HR 4.66, fulfillment of the imaging arm HR 6.64 and HLA-B27+ HR 3.99 by Poddubnyy et al #EULAR2022 @RheumNow OP0149
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0139
Has your pt asked about sexual fxn?
Sexual dysfxn (SD) (CSFQ-14 questionnaire) and joint disease
188 AI pts, 89 controls
Nearly 50% of RA pts had SD, 30% in PsA. Only 6% in control group!
High depression in group, but not found as rf
@RheumNow https://t.co/WvBw3cnFKC
Janet Pope Janetbirdope
3 years 6 months ago
#ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refractory #lupus, antiCD38i, drugs i. RCTs=hope for pts. #EULAR2022 T Dorner @RheumNow @eular_org https://t.co/2BReU5bhG0
Richard Conway RichardPAConway
3 years 6 months ago
Tang et al. Prediction of 6-month mortality in MDA5-DM. Fever, ferritin≥1250, and positive carcinoembryonic antigen (CEA) predictive in Chinese population @RheumNow #EULAR2022 OP0163 https://t.co/byDiHZhcGK https://t.co/95Wx4quQMP
TheDaoIndex KDAO2011
3 years 6 months ago
No need to switch TNFi during pregnancy. Study compared high placental vs. low placental transfer TNFi- no sig difference for SIE in childhood. Dr. L Flatman comparing different TNFi in pregnancy: 26,000 offsprings #EULAR2022 @rheumnow OP0130 https://t.co/IF5hepQoHc
Janet Pope Janetbirdope
3 years 6 months ago
#SLE hospitalized pts had worse outcomes than matched controls ? Due to interfonopathy and poor handling of viral infections - worse if #Rituximab or #MMF T Dormer BUT vaccination works if enough B cells responding to #Covid vaccine #EULAR2022 #Lupus scientific session @RheumNow https://t.co/MBb3Dvxmqp
Dr. Antoni Chan synovialjoints
3 years 6 months ago
The GESPIC cohort reports in Axial PsA, 75% had inflammatory back pain, 45% met NY criteria for AS, 55% with active inflammatory change in SI joint and 60% in the spine. This is where the overlap between Axial PsA and Axial SpA happens, Kading et al #EULAR2022 @RheumNow OP0026
Aurelie Najm AurelieRheumo
3 years 6 months ago
Pregnancy outcomes in SpA
Increased risk of
❗️gestational diabetes aRR 1.88
❗️Cesarean delivery aRR 1.54 & 1.23
❗️preterm birth aRR 1.52
❗️trend for increased infection
in 1st year of life in newborns aRR 1.23.
#EULAR2022 @RheumNow OP0126 https://t.co/jMryB5UXQr
TheDaoIndex KDAO2011
3 years 6 months ago
Million $$$ questions presented to Prof T Dorner: anifrolumab vs. belimumab for #SLE? He prefers belimumab d/t more data on multiple organ manifestations ^ it might be protective in pts w/ COVID19 infection. If skin dz is predominant, then anifrolumab #EULAR2022
@rheumnow
David Liew drdavidliew
3 years 6 months ago
Patient with 12 weeks inflamm-sounding arthralgias and functional impairment, high titre RF/CCP, osteitis on MRI, no clinical synovitis on exam.
Do you suggest to patient to treat with methotrexate?
#EULAR2022 @RheumNow
David Liew drdavidliew
3 years 6 months ago
What does avacopan mean for sustained remission in AAV?
New post-hoc from ADVOCATE - keeping in mind the avacopan was instead of steroids. Impressive numbers, so increasingly the questions will be about strategy and cost?
#EULAR2022 @RheumNow https://t.co/B4y8jZiHf5
Poster Hall